FMRP detection assay for the diagnosis of the fragile X syndrome
1Department of Clinical Genetics, Erasmus University, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.
Abstract:
Fragile X syndrome is almost always caused by the absence or deficit of the FMR1 protein (FMRP). Diagnostic methods include polymerase chain reaction and Southern blotting, which are performed on DNA isolated from peripheral leukocytes. Recently, different immunocytochemical tests have been described to identify patients with fragile X syndrome, based on the detection of FMRP in cells by a monoclonal antibody. This review aims to provide an update on the different antibody methods for prenatal and postnatal diagnosis of the fragile X syndrome.
Insights
Fragile X syndrome diagnosis is improving. New antibody-based immunocytochemical tests detect the fragile X mental retardation protein (FMRP), offering an update on prenatal and postnatal diagnostic methods.
Area of Science:
- Genetics
- Immunology
- Molecular Biology
Background:
- Fragile X syndrome is primarily caused by a deficiency of the fragile X mental retardation protein (FMRP).
- Current diagnostic methods rely on DNA analysis (PCR, Southern blotting) from peripheral leukocytes.
- There is a need for updated diagnostic approaches for Fragile X syndrome.
Purpose of the Study:
- To review and update current knowledge on antibody-based immunocytochemical methods for Fragile X syndrome diagnosis.
- To highlight the utility of monoclonal antibodies in detecting FMRP for diagnostic purposes.
- To provide an overview of these methods for both prenatal and postnatal applications.
Main Methods:
- Review of existing literature on immunocytochemical techniques for Fragile X syndrome.
- Focus on monoclonal antibody-based detection of FMRP in cells.
- Discussion of applications in prenatal and postnatal diagnostics.
Main Results:
- Immunocytochemical tests using monoclonal antibodies are emerging as viable methods for Fragile X syndrome diagnosis.
- These methods allow for the direct detection of FMRP, complementing traditional DNA-based approaches.
- Antibody-based detection offers potential for improved diagnostic capabilities.
Conclusions:
- Immunocytochemical methods utilizing monoclonal antibodies represent a significant advancement in Fragile X syndrome diagnostics.
- These antibody-based approaches provide valuable tools for both prenatal and postnatal identification of the condition.
- Further development and validation of these methods are crucial for clinical implementation.
More Related Videos
11:10Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
Published on: July 6, 2022
08:13Robust Comparison of Protein Levels Across Tissues and Throughout Development Using Standardized Quantitative Western Blotting
Published on: April 9, 2019